Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Mohamad-Gabriel Alameh,István Tombácz,Emily Bettini,Katlyn Lederer,Chutamath Sittplangkoon,Joel R Wilmore,Brian T Gaudette,Ousamah Y Soliman,Matthew Pine,Philip Hicks,Tomaz B Manzoni,James J Knox,John L Johnson,Dorottya Laczkó,Hiromi Muramatsu,Benjamin Davis,Wenzhao Meng,Aaron M Rosenfeld,Shirin Strohmeier,Paulo J C Lin,Barbara L Mui,Ying K Tam,Katalin Karikó,Alain Jacquet,Florian Krammer,Paul Bates,Michael P Cancro,Drew Weissman,Eline T Luning Prak,David Allman,Michela Locci,Norbert Pardi
DOI: https://doi.org/10.1016/j.immuni.2021.11.001
IF: 32.4
2021-12-14
Immunity
Abstract:Adjuvants are critical for improving the quality and magnitude of adaptive immune responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines have shown great efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mechanism of action of this vaccine platform is not well-characterized. Using influenza virus and SARS-CoV-2 mRNA and protein subunit vaccines, we demonstrated that our LNP formulation has intrinsic adjuvant activity that promotes induction of strong T follicular helper cell, germinal center B cell, long-lived plasma cell, and memory B cell responses that are associated with durable and protective antibodies in mice. Comparative experiments demonstrated that this LNP formulation outperformed a widely used MF59-like adjuvant, AddaVax. The adjuvant activity of the LNP relies on the ionizable lipid component and on IL-6 cytokine induction but not on MyD88- or MAVS-dependent sensing of LNPs. Our study identified LNPs as a versatile adjuvant that enhances the efficacy of traditional and next-generation vaccine platforms.